<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04542824</url>
  </required_header>
  <id_info>
    <org_study_id>GCT3013-04</org_study_id>
    <nct_id>NCT04542824</nct_id>
  </id_info>
  <brief_title>Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With R/R B-NHL</brief_title>
  <official_title>Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3×CD20) in Japanese Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A Phase 1/2, Open-Label, Dose-Escalation Trial With Expansion Cohorts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genmab</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Genmab</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the trial is to determine the maximum tolerated dose and/or the recommended&#xD;
      phase 2 dose as well as to establish the safety profile of epcoritamab in Japanese patients&#xD;
      with Relapsed, Progressive or Refractory B-Cell Lymphomas.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial is an open-label, multi-center safety trial of epcoritamab. The trial consists of&#xD;
      two parts: Part 1, dose escalation (phase 1), and Part 2, expansion (phase 2). The expansion&#xD;
      part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) has been&#xD;
      determined in Part 1.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Part 1: Sequential Assignment&#xD;
Part 2: Single Group Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Escalation:Adverse Events (AEs) to determine the Recommended Phase 2 Dose (RP2D)</measure>
    <time_frame>Adverse events are assessed during the first cycle (28 days) in each cohort</time_frame>
    <description>• Number of AEs, treatment emergent AEs as assessed by CTCAE V5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Escalation: Dose limiting toxicities (DLTs) to determine the RP2D.</measure>
    <time_frame>DLTs are assessed during the first cycle (28 days) in each cohort</time_frame>
    <description>• Number of DLTs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Expansion: Objective response rate (ORR) to evaluate clinical efficacy</measure>
    <time_frame>Up to 3 years after last patient dosed in the trial, through study completion</time_frame>
    <description>• Antitumor activity as measured by the ORR according to Lugano classification</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Escalation and Expansion: Pharmacokinetic parameters, Cmax</measure>
    <time_frame>During the first cycle (28 days) for each patient</time_frame>
    <description>• Peak Concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Escalation and Expansion: Pharmacokinetic parameters, AUC</measure>
    <time_frame>During the first cycle (28 days) for each patient</time_frame>
    <description>•Area under the concentration versus time curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Escalation and Expansion: Pharmacokinetic parameters, C trough</measure>
    <time_frame>Up to 3 years after last patient dosed in the trial, through study completion</time_frame>
    <description>•Trough Concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Escalation and Expansion: Anti-Drug-Antibodies (ADAs) to evaluate immunogenicity</measure>
    <time_frame>Up to 3 years after last patient dosed in the trial, through study completion</time_frame>
    <description>•ADAs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Escalation and Expansion: Safety laboratory parameters (hematology)</measure>
    <time_frame>Up to 3 years after last patient dosed in the trial, through study completion</time_frame>
    <description>•CTCAE Grade changes from Baseline of hematology parameters: Hemoglobin, hematocrit, white blood cells including differential, neutrophils, basophils, eosinophils, absolute and percentage of lymphocytes, monocytes, reticulocytes, platelets, proportion of prolymphocytes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Escalation and Expansion: Safety laboratory parameters (biochemistry)</measure>
    <time_frame>Up to 3 years after last patient dosed in the trial, through study completion</time_frame>
    <description>•CTCAE Grade changes from baseline of biochemistry parameters: albumin, alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), bicarbonate, lactate dehydrogenase (LDH), calcium, chloride, magnesium, inorganic phosphorus (phosphate), sodium, potassium, creatinine, total bilirubin, blood urea nitrogen (BUN) or urea, uric acid, glucose, total protein, C reactive protein, D-dimer, ferritin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Escalation and Expansion: Safety laboratory parameters (coagulation)</measure>
    <time_frame>Up to 3 years after last patient dosed in the trial, through study completion</time_frame>
    <description>•CTCAE Grade changes from Baseline of coagulation parameters: International normalized ratio (INR), activated partial thromboplastin time (aPTT), and fibrinogen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Escalation and Expansion: Cytokine measures to evaluate safety and tolearability</measure>
    <time_frame>During the first 3 cycles for each patient (each cycle is 28 days)</time_frame>
    <description>•Plasma levels of cytokines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansion: AEs to evaluate safety and tolerability</measure>
    <time_frame>Up to 3 years after last patient dosed in the trial, through study completion</time_frame>
    <description>•Number of AEs, treatment emergent AEs as assessed by CTCAE V5.0.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">73</enrollment>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <condition>High-grade B-cell Lymphoma</condition>
  <condition>Primary Mediastinal Large B Cell Lymphoma</condition>
  <condition>Follicular Lymphoma</condition>
  <condition>Marginal Zone Lymphoma</condition>
  <condition>Small Lymphocytic Lymphoma</condition>
  <arm_group>
    <arm_group_label>epcoritamab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label, single arm trial where epcoritamab will be administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>epcoritamab</intervention_name>
    <description>Epcoritamab will be administered subcutaneously in cycles of 4 weeks i.e. 28 days. The dose-levels will be determined by the starting dose and the escalation steps taken in the trial.</description>
    <arm_group_label>epcoritamab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          -  Must be at least 20 years of age, inclusive&#xD;
&#xD;
          -  Japanese subjects&#xD;
&#xD;
          -  Documented CD20 positive mature B-cell neoplasm&#xD;
&#xD;
               1. Part 1 - dose escalation:&#xD;
&#xD;
                    -  Diffuse large B-cell lymphoma (de novo or histologically transformed)&#xD;
&#xD;
                    -  High-grade B-cell lymphoma&#xD;
&#xD;
                    -  Primary mediastinal large B-cell lymphoma&#xD;
&#xD;
                    -  Follicular lymphoma&#xD;
&#xD;
                    -  Marginal zone lymphoma (nodal, extranodal of mucosa-associated lymphoid&#xD;
                       tissue, or splenic)&#xD;
&#xD;
                    -  Small lymphocytic lymphoma&#xD;
&#xD;
               2. Part 2 - expansion:&#xD;
&#xD;
                    -  Diffuse large B-cell lymphoma (de novo or histologically transformed)&#xD;
&#xD;
                    -  Follicular lymphoma grade 1-3A&#xD;
&#xD;
          -  Relapsed or refractory disease and previously treated with at least 2 lines of&#xD;
             systemic antineoplastic therapy including at least 1 anti-CD20 mAb-containing therapy.&#xD;
&#xD;
          -  Measurable disease by CT, MRI or PET-CT scan&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  Primary CNS lymphoma or CNS involvement by lymphoma&#xD;
&#xD;
          -  Subjects not eligible for high dose therapy with autologous hematopoietic stem cell&#xD;
             transplantation due to personal choice, social issues, or similar&#xD;
&#xD;
          -  AST and/or ALT &gt; 3 xULN&#xD;
&#xD;
          -  Total bilirubin &gt; 1.5 xULN (unless due to Gilbert syndrome)&#xD;
&#xD;
          -  Creatinine clearance &lt; 45 mL/min&#xD;
&#xD;
          -  Known clinically significant cardiac disease&#xD;
&#xD;
          -  Chronic ongoing infectious diseases requiring treatment (excluding prophylactic&#xD;
             treatment)&#xD;
&#xD;
          -  Exposed to live or live attenuated vaccine within 4 weeks before the first dose of&#xD;
             epcoritamab&#xD;
&#xD;
          -  Active hepatitis B (HepB DNA positive) or hepatitis C (HepC RNA positive)&#xD;
&#xD;
          -  Known history or positive test results confirming HIV infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rebecca Valentin, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Genmab</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Genmab A/S Trial Information</last_name>
    <phone>+45 70202728</phone>
    <email>clinicaltrials@genmab.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aichi Cancer Center Hospital</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NHO Kyushu Cancer Center</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fukushima Medical University Hospital</name>
      <address>
        <city>Fukushima</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kagoshima University Hospital</name>
      <address>
        <city>Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kanazawa University Hospital</name>
      <address>
        <city>Kanazawa</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyoto University Hospital</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Matsuyama Red Cross Hospital</name>
      <address>
        <city>Matsuyama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Nagoya Daini Hospital</name>
      <address>
        <city>Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NHO Nagoya Medical Center</name>
      <address>
        <city>Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Genmab Investigational site JP002</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Sendai</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cancer Institute Hospital of JFCR</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Tsukuba Hospital</name>
      <address>
        <city>Tsukuba</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mie University Hospital</name>
      <address>
        <city>Tsu</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yamagata University Hospital</name>
      <address>
        <city>Yamagata</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 25, 2020</study_first_submitted>
  <study_first_submitted_qc>September 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2020</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

